Page 4 - ப்ரெக்கன்ரிட்ஜ் மருந்து இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nifty regains 15,700 mark; breadth negative

Nifty regains 15,700 mark; breadth negative
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

India generalNew jerseyUnited statesTamil naduNatco pharmaWelspun corpAdani enterprisesSun tv networkMinistry of healthBreckenridge pharmaceutical incNational statistical officeWholesale price indexIndustrial productionFamily welfareNifty metalCoal india

Natco marketing partner gets approval for Carfilzomib Vials in the US market

Natco marketing partner gets approval for Carfilzomib Vials in the US market
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Drug administrationBreckenridge pharmaceutical incOnyx therapeutics incNatco pharmaNatco pharma limitedAbbreviated new drug applicationCarfilzomib vialsOnyx therapeuticsப்ரெக்கன்ரிட்ஜ் மருந்து இன்க்ஓனிக்ஸ் சிகிச்சை இன்க்நாட்கோ பார்மாநாட்கோ பார்மா வரையறுக்கப்பட்டவைஓனிக்ஸ் சிகிச்சை

Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Zortress®)

Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Zortress®) News provided by Share this article Share this article BERLIN, Conn., June 1, 2021 /PRNewswire/ Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress ®). This product was developed in collaboration with Natco Pharma Limited. According to industry sales data, Zortress and its therapeutic equivalents generated annual sales of $162 million during the twelve months ending March 2021. Breckenridge plans to launch Everolimus Tablets in 0.25mg, 0.5mg and 0.75mg strengths during the third quarter of 2021 in a blister card packaging configuration.

United statesRobert gasparinoDrug administrationBreckenridge pharmaceutical incPrnewswire breckenridge pharmaceutical incBusiness developmentNatco pharmaAbbreviated new drug applicationEverolimus tabletsTowa pharmaceuticalPharma limitedAssociate vice presidentBreckenridge pharmaceuticalஒன்றுபட்டது மாநிலங்களில்ராபர்ட் கஸ்பரினோப்ரெக்கன்ரிட்ஜ் மருந்து இன்க்

Natco Pharma hits record highs on drug approvals - The Hindu BusinessLine

Natco Pharma hits record highs on drug approvals May 24, 2021 The shares of Natco Pharma hit record highs on Monday. At 12:20 pm, Natco Pharma was trading at ₹1,088.00 on the BSE, up ₹97.20 or 9.81 per cent. It opened at a 52-week high of ₹1,188.95 as against the previous close of ₹990.80. On the NSE, it was trading at ₹1,088.95, up ₹98.90 or 9.99 per cent. It hit a 52-week high of ₹1,188.05. The company has been in focus after being among the five new companies roped in by the Centre last week to produce Amphotericin B that is used to treat Mucormycosis (black fungus) to combat the shortages being reported in parts of the country.

United statesNatco pharmaArrow international limitedDrug administrationBreckenridge pharmaceutical incTeva pharmaceutical industries ltdUnited states foodAbbreviated new drug applicationLenalidomide capsulesBreckenridge pharmaceuticalEverolimus tabletsNatco pharma stocksNatco pharma stocks riseNatco pharma stock highஒன்றுபட்டது மாநிலங்களில்நாட்கோ பார்மா

Why Natco Pharma share zoomed 20% today- Business News

Why Natco Pharma share zoomed 20% today Presently six firms - BDR Pharma, Bharat Serums and Vaccines, Mylan, Sun Pharma, Cipla, and Life Care - are producing Amphotericin B BusinessToday.In | May 24, 2021 | Updated 12:17 IST Representative Image Share of Natco Pharma rose 20 per cent to hit a fresh 52-week high of Rs 1188.95 in early tradeafter the Drug Controller General of India (DCGI) gave its nod to the firm start manufacturing antifungal anti-fungal drug Amphotericin B liposomal injection. Its demand has increased in the wake of a surge in black fungus infections. Four other firms Alembic Pharmaceuticals, Emcure Pharmaceuticals, Gufic Biosciences and Lyca Pharmaceuticals have also received DCGI s permission to produce the injection.

Sun pharmaGufic biosciencesMansukh mandaviyaNatco pharmaAlembic pharmaceuticalsLyca pharmaceuticalsEmcure pharmaceuticalsDrug administrationIndian companiesCentral drugs standard control organizationBreckenridge pharmaceutical incDrug controller generalBharat serumsLife careFertilisers mansukh mandaviyaBreckenridge pharmaceutical